Weed (BUDZ) Total Non-Current Liabilities (2023 - 2026)
Weed's (BUDZ) quarterly Total Non-Current Liabilities came in at $1.3 million in Q1 2026, up 48.77% year-on-year from $885564.0 in Q1 2025, and up 8.66% quarter-over-quarter from $1.2 million in Q4 2025.
Weed (BUDZ) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Weed's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 48.77% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 48.77% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 31.28% from the prior year.
- Total Non-Current Liabilities rose to $1.3 million in Q1 2026 per BUDZ's latest filing, from $1.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.3 million in Q1 2026 and bottomed at $559979.0 in Q2 2024.
- The 4-year median for Total Non-Current Liabilities is $904568.0 (2024), against an average of $869833.2.
- Biggest YoY gain for Total Non-Current Liabilities was 71.62% in 2025; the steepest drop was 31.28% in 2025.
- Year by year, Total Non-Current Liabilities stood at $612953.0 in 2023, then surged by 50.68% to $923572.0 in 2024, then jumped by 31.28% to $1.2 million in 2025, then grew by 8.66% to $1.3 million in 2026.
- Per Business Quant, the three latest BUDZ Total Non-Current Liabilities figures stand at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - | 1.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.32 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 961,033.00 |
| Mar 31, 2025 | 885,564.00 |
| Dec 31, 2024 | 923,572.00 |
| Sep 30, 2024 | 649,245.00 |
| Jun 30, 2024 | 559,979.00 |
| Mar 31, 2024 | 560,533.00 |
| Dec 31, 2023 | 612,953.00 |